Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16-Week randomized, double-blind, placebo-controlled study

Riikka Lautamaki; K.E. Juhani Airaksinen; Marko Seppanen; Jyri Toikka; Matti Luotolahti; Elizabeth Ball; Ronald Borra; Risto Harkonen; Patricia Iozzo; Murray Stewart; Juhani Knuuti; Pirjo Nuutila

Clinical Diabetology
Vol 6, No 6 (2005): Practical Diabetology Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16-Week randomized, double-blind, placebo-controlled study

Vol 6, No 6 (2005): Practical Diabetology

Other materials agreed with the Editors

Published online: 2005-11-03

Page views 591

Article views/downloads 0

Get Citation

Connect on Social Media

Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16-Week randomized, double-blind, placebo-controlled study

Riikka Lautamaki, K.E. Juhani Airaksinen, Marko Seppanen, Jyri Toikka, Matti Luotolahti, Elizabeth Ball, Ronald Borra, Risto Harkonen, Patricia Iozzo, Murray Stewart, Juhani Knuuti, Pirjo Nuutila

Diabetologia Praktyczna 2005;6(6):357-368.

Abstract

Not available

Keywords: insulin sensitivityglucose uptaketype 2 diabetes mellitus

Connect on Social Media

Connect on Social Media

E-mail alerts

Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16-Week randomized, double-blind, placebo-controlled study

Abstract